Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)

• Published in: The European journal of contraception & reproductive health care Vol. 22; no. 6; pp. 429 - 438
• Main Authors: Algorta, Jaime, Diaz, Maria, de Benito, Raquel, Lefebvre, Marc, Sicard, Eric, Furtado, Milton, Regidor, Pedro Antonio, Ronchi, Celestino
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.11.2017; Taylor & Francis Ltd
• Subjects: acceptability; Bioequivalence; burst effect; comparative bioavailability; contraceptive vaginal ring; ethinylestradiol; Etonogestrel; Pharmacokinetics; Polymers; user satisfaction; Vagina; Spain; Etonogestrel; comparative bioavailability; ethinylestradiol; contraceptive vaginal ring; burst effect; acceptability; user satisfaction

Objective: To show the clinical development of Ornibel ® (ExeltisHealthcare, Spain) a contraceptive vaginal ring manufactured with a new polymer composition and containing etonogestrel/ethinylestradiol, compared to Nuvaring ® (MSD, Spain). Subjects and methods: Randomised, single dose, 2-period, 2-s...